01.12.2017 | Case report
Afatinib/erlotinib/osimertinib
Development of drug resistence due to acquired EGFR mutation leading to disease progression: case report
Erschienen in: Reactions Weekly | Ausgabe 1/2017
Einloggen, um Zugang zu erhaltenExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event